New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: A pooled analysis of the randomized trials

Cancer

Volumn 104, Issue 7, 2005, Pages 1335-1342

  Carlini, Paolo ^a   Bria, Emilio ^a   Giannarelli, Diana ^a   Ferretti, Gianluigi ^a   Felici, Alessandra ^a   Papaldo, Paola ^a   Fabi, Alessandra ^a   Nisticò, Cecilia ^a   Di Cosimo, Serena ^a   Ruggeri, Enzo Maria ^a   Milella, Michele ^a   Mottolese, Marcella ^a   Terzoli, Edmondo ^a   Cognetti, Francesco ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Aromatase inhibitors; Comprehensive review; Metaanalysis; Metastatic breast carcinoma; Pooled analysis

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; FADROZOLE; FORMESTANE; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN; VOROZOLE;

BREAST CARCINOMA; CANCER GROWTH; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; DYSPNEA; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HOT FLUSH; HUMAN; META ANALYSIS; METASTASIS; NAUSEA; PERIPHERAL EDEMA; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; WEIGHT GAIN;

AGED; ANDROSTENEDIONE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARCINOMA; CLINICAL TRIALS, PHASE III; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FADROZOLE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; POSTMENOPAUSE; PROBABILITY; PROGNOSIS; REMISSION INDUCTION; RISK ASSESSMENT; SURVIVAL ANALYSIS; TRIAZOLES;

EID: 25144511359     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21339     Document Type: Review

References (31)

1. Forbes JF. The control of breast cancer: the role of tamoxifen. Semin Oncol. 1997;24(Suppl 1):S1-5-S-19.
2. Powles TJ. Efficacy of tamoxifen as treatment of breast cancer. Semin Oncol. 1997;24(Suppl 1):S1-48-S1-54.
3. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998;351:1451-1467.
4. Bonneterie J, Thürlimann BJK, Robertson JFR. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomized group efficacy and tolerability study. J Clin Oncol. 2000;18:3748-3757.
5. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol. 2000;18:3758-3767.
6. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001;19:2596-2606.
7. Miller WR. Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat Rev. 1989;16:83-93.
8. Lonning PE. Cross-resistance to different aromatase inhibitors in breast cancer treatment. Endocr Relat Cancer. 1999; 6:251-257.
9. Buzdar AU, Robertson JFR, Eiermann W, et al. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer. 2002;95:2006-2016.
10. Buzdar AU, Smith R, Vogel C, et al. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. Cancer. 1996;77:2503-2513.
11. Goss PE, Winer EP, Tannock IF, et al. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. J Clin Oncol. 1999;17:52-63.
12. Thurlimann B, Castiglione M, Hsu-Schmitz SF, et al. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Eur J Cancer. 1997;33:1017-1024.
13. Freue M, Kjaer M, Boni C, et al. Open comparative trial of formestane versus megestrol acetate in postmenopausal patients with advanced breast cancer previously treated with tamoxifen. Breast. 2000;9:9-16.
14. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer. 1998;83:1142-1152.
15. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998;16:453-461.
16. Buzdar A, Douma N, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol. 2001;19:3357-3366.
17. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol. 2000;18:1399-1411.
18. Buzdar A, Howell A. Advances in aromatase inhibition. Clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res. 2001;7:2620-2635.
19. Hamilton A, Piccart M. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol. 1999;10:377-384.
20. Messori A, Cattel F, Trippoli S, et al. Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol. Anticancer Drugs. 2000;11:701-706.
21. Simes RJ. Confronting publication bias: a cohort design for meta-analysis. Stat Med. 1987;6:11-29.
22. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815-2834.
23. Douglas Case L, Kimmick G, Paskett ED, Lohman K, Tucker R. Interpreting measures of treatment effect in cancer clinical trials. Oncologist. 2002;7:181-187.
24. Bria E, Giannarelli D, Felici A, et al. Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma. Cancer. 2005;103:672-679.
25. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131-2139.
26. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793-1802.
27. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081-1092.
28. Goss PE, Strasser-Weippl K. Aromatase inhibitors for chemoprevention. Best Pract Res Clin Endocrinol Metab. 2004;18:113-130.
29. Di Leo A, Bleiberg H. Overall survival is not a realistic endpoint for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol. 2003;21:2045-2047.
30. Verma S, Rocchi A. Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer. Support Care Cancer. 2003;11:728-734.
31. Dranitsaris G, Leung P, Mather J, et al. Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate. Anticancer Drugs. 2000;7:591-601.